Salman Aly, MD
Internal Medicine · Sugar Land, TXNPI 1326287715
Payments from drug & device makers
Across 316 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$5K
- AbbVie$1K
- Mimedx Group, Inc.$592
- Reddress USA, Inc.$372
- Boston Scientific$290
- AstraZeneca$277
- plus $2K from 34 others
What the payments were for
- Food & beverage$9,50299%
- Education$1341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 139 | $4,710 |
| AbbVie(2 entities) | 82 | $1,356 |
| Mimedx Group, Inc. | 10 | $592 |
| Reddress USA, Inc. | 2 | $372 |
| Boston Scientific | 2 | $290 |
| AstraZeneca | 3 | $277 |
| Revance Therapeutics, Inc. | 6 | $262 |
| Senseonics, Incorporated | 4 | $157 |
| Osiris Therapeutics Inc. | 8 | $152 |
| Organogenesis Inc. | 8 | $152 |
| Pfizer | 6 | $122 |
| Astellas Pharma US Inc | 2 | $119 |
| Abbott | 1 | $108 |
| Hartmann USA, Inc. | 4 | $105 |
| Merck | 4 | $98 |
| Paratek Pharmaceuticals, Inc. | 4 | $81 |
| Lilly USA, LLC | 1 | $76 |
| ETS Wound Care LLC | 1 | $73 |
| Misonix Inc | 1 | $61 |
| Johnson & Johnson | 3 | $54 |
| Eisai Inc. | 2 | $41 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $35 |
| Convatec Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Insmed, Inc. | 1 | $27 |
| Galderma Laboratories, L.p. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Shionogi Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Solventum Corporation | 1 | $16 |
| Novartis | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Urgo Medical North America, LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Reapplix Inc. | 1 | $12 |
| Medela LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GRAFIX PL$729
- PICO Single Use Negative Pressure Wound Therapy$318
- EKOSONIC$290
- RENASYS TOUCH$277
- FARXIGA$255
- DALVANCE$250
- RENASYS GO$247
- PICO 7 Single Use Negative Pressure Wound Therapy$150
- Stravix$139
- BOTOX$137
- PICO7$124
- Grafix$122
- PROCLAIM$108
How this compares
$9,636 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 400 | $183,160 |
| IngrezzaValbenazine Tosylate | 42 | $164,243 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 22 | $93,304 |
| JardianceEmpagliflozin | 120 | $92,713 |
| OzempicSemaglutide | 67 | $85,765 |
| GemtesaVibegron | 252 | $66,472 |
| TrulicityDulaglutide | 54 | $61,634 |
| MounjaroTirzepatide | 50 | $60,082 |
| NuplazidPimavanserin Tartrate | 23 | $56,098 |
| Invega SustennaPaliperidone Palmitate | 21 | $55,837 |
| JanuviaSitagliptin Phosphate | 90 | $54,514 |
| XareltoRivaroxaban | 111 | $40,082 |
| TivicayDolutegravir Sodium | 16 | $36,227 |
| FarxigaDapagliflozin Propanediol | 48 | $35,870 |
| RybelsusSemaglutide | 18 | $33,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $183,160400 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $76 | $121,716104 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $54 | $95,919132 claims |
| MerckJanuvia | $98 | $54,51490 claims |
| AstraZenecaFarxiga, Symbicort | $277 | $42,69574 claims |
| NovartisEntresto | $15 | $23,82757 claims |
| AbbVieLinzess | $1,356 | $18,78923 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $16,62526 claims |
| Smith+NephewSantyl | $4,710 | $14,54631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sugar Land
- Harish ThakkarSugar Land$6.3M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.